Xeris Biopharma ( XERS ) Upgraded to Buy: Here's Why
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris ( XERS ) Q2 Revenue Jumps 49%
Xeris Biopharma ( NASDAQ:XERS ) , a specialty pharmaceutical company focused on developing and commercializing injectable therapies, reported its Q2 2025 earnings on August 7, 2025. The release revealed record revenue and a notable swing to positive adjusted earnings before interest, taxes, ...
Xeris Biopharma ( XERS ) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of +66.67% and +10.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics ( ZVRA ) Moves 5.1% Higher: Will This Strength Last?
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma ( XERS ) Reports Q1 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 14.29% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics ( CORT ) Meets Q1 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of 0% and 11.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Xeris Biopharma ( XERS ) : Can Its 5.6% Jump Turn into More Strength?
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Xeris Biopharma ( XERS ) Reports Q4 Loss, Misses Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Verrica Pharmaceuticals Inc. ( VRCA ) Expected to Beat Earnings Estimates: Should You Buy?
Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics ( ACRS ) Reports Q4 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma ( XERS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - Applied Therapeutics ( NASDAQ:APLT ) , Reviva Pharmaceuticals ( NASDAQ:RVPH )
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer NEW YORK, Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Applied Therapeutics, Inc. APLT, a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the ...
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sapiens Intl Corp ( NASDAQ:SPNS )
U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday. Shares of Sapiens International Corporation N.V. SPNS fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results.
Xeris Biopharma ( XERS ) Reports Q3 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 33.33% and 5.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. ( VYNE ) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics ( ZVRA ) Moves 9.1% Higher: Will This Strength Last?
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying - Precigen ( NASDAQ:PGEN )
The Dow Jones index closed higher by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying - Solo Brands ( NYSE:DTC ) , One Group Hospitality ( NASDAQ:STKS )
The Dow Jones index closed lower by over 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Xeris Biopharma ( XERS ) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 9.09% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals ( AMRX ) Q2 Earnings Expected to Decline
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Xeris Biopharma ( XERS ) Report Negative Earnings Next Week? What You Should Know
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals ( IONS ) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 52.63% and 52.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma ( XERS ) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying - Socket Mobile ( NASDAQ:SCKT )
The Dow Jones index closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...
Xeris Biopharma ( XERS ) Reports Q1 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Are Xeris Biopharma Shares Moving Monday? - Xeris Biopharma Holdings ( NASDAQ:XERS )
Xeris Biopharma Holdings, Inc XERS shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics.
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
CONCORD, MA / ACCESSWIRE / May 6, 2024 / Xeris Biopharma Holdings, Inc. ( Nasdaq:XERS ) , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into ...
Strength Seen in MediWound ( MDWD ) : Can Its 14.3% Jump Turn into More Strength?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma ( XERS ) Reports Q4 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -11.11% and 2.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics ( AQST ) Reports Q4 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Xeris ( XERS ) Might Surprise This Earnings Season
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Xeris ( XERS ) Up on Licensing Deal With Amgen to Develop Tepezza
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday - Allstate ( NYSE:ALL ) , Agiliti ( NYSE:AGTI )
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. LW rose during Thursday's session following better-than-expected quarterly results. Lamb Weston posted adjusted earnings of $1.45 per share, beating market ...
Penny Stocks to Buy? 3 To Watch With Insider Trading In November
Penny stocks, usually under $5 a share, draw traders looking for big gains. But these stocks can be risky. A smart move is to watch insider trading through SEC filings. Insiders like company directors and officers have access to key info that isn't public. Their trading moves can give investors ...
Taro Pharmaceutical ( TARO ) Tops Q2 Earnings Estimates
Taro (TARO) delivered earnings and revenue surprises of 111.11% and 8.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Xeris Biopharma Shares Are Trading Higher Today
Xeris Biopharma Holdings Inc ( NASDAQ:XERS ) shares are trading higher by around 9% after the company revised its FY23 outlook. The company raised the lower end of its revenue guidance, revising the range to $155 million-$165 million ( vs. consensus of $158.2 million ) from $145 million-$165 ...
Why Xeris Biopharma ( XERS ) Shares Are Trading Higher Today - Xeris Biopharma Holdings ( NASDAQ:XERS )
Xeris Biopharma Holdings Inc XERS shares are trading higher by around 9% after the company revised its FY23 outlook. The company raised the lower end of its revenue guidance, revising the range to $155 million-$165 million ( vs. consensus of $158.2 million ) from $145 million-$165 million.
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors - Larimar Therapeutics ( NASDAQ:LRMR )
BALA CYNWYD, Pa., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W.
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
BALA CYNWYD, Pa., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W.
Ironwood ( IRWD ) Surges 7.6%: Is This an Indication of Further Gains?
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.
$8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - Vicarious Surgical ( NYSE:RBOT ) , Container Store Group ( NYSE:TCS )
The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Ocular Therapeutix ( OCUL ) Reports Q2 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Character of the Market Is Shifting: Here's What to Watch
For the second day in a row, the indexes are seeing strong selling pressure. This is the third session out of the last six where the bears took control. Breadth is running about 2500 gainers to 5800 decliners, and there are more stocks hitting new 12-month lows than highs.
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday - XIAO-I ( NASDAQ:AIXI ) , Alvotech ( NASDAQ:ALVO )
BioXcel Therapeutics, Inc. BTAI shares dropped 62.2% to $6.68 after the company released topline results from TRANQUILITY II Phase 3 trial of BXCL501 for acute treatment of Alzheimer's Disease-related agitation. Liquidia Corporation LQDA fell 15% to $8.42.
Ocular Therapeutix ( OCUL ) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
FDA Grants Orphan-drug Exclusivity For Xeris' Recorlev For Endogenous Cushing's Syndrome Treatment
( RTTNews ) - Xeris Biopharma Holdings Inc. ( XERS ) said Monday that the U.S. Food and Drug Administration granted its subsidiary Xeris Pharmaceuticals Inc., orphan-drug exclusivity for Recorlev ( levoketoconazole ) for the treatment of adult patients with endogenous Cushing's syndrome for whom ...
Xeris ( XERS ) , Horizon to Develop Ready-to-Use Teprotumumab
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Concert Pharmaceuticals ( CNCE ) Reports Q3 Loss, Misses Revenue Estimates
Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
